Bernadette Murdoch, an experienced Australian and global corporate affairs and communications leader across multiple industries, will join CSL and lead its global Reputation Management Center of Excellence (CoE).
14 Sep 2022
Bernadette Murdoch, an experienced Australian and global corporate affairs and communications leader across multiple industries, will join CSL and lead its global Reputation Management Center of Excellence (CoE) within the Corporate Affairs & Communications function, effective in November. She will be based in Parkville and, among her responsibilities, coordinate media relations in Australia.
Murdoch joins CSL after serving in a series of progressive communications leadership roles both within biopharma as well as other industries. Since 2017, she has worked at global mining leader Rio Tinto, including serving as Head of global Reputation & Brand.
For 11 years, Murdoch served in a variety of leadership roles at global healthcare leader GSK including multiple assignments in London and Melbourne, where she led corporate affairs & communications for GSK’s Australasia region. Earlier in her career, she worked for several communications agencies including global leader Burson-Marsteller.
Additionally, Murdoch is involved with several non-profit organizations in the surrounding Melbourne community including serving on the Board of Directors for the Lord Mayor’s Charitable Foundation, Australia's largest community foundation.
“With Bernadette, we are absolutely thrilled to have such a proven Australian and global leader join CSL,” said CSL’s Chief Communications & Brand Officer Anthony Farina. “Building and protecting CSL’s reputation has never been more important with our new branding now launched. Bernadette will provide demonstrated leadership in the formulation, development and implementation of reputation management strategies -- assuring CSL continues to foster its strong reputation with key stakeholders around the world, including in our headquarters community of Australia.”
P: +61 450 909 211
CSL Limited (ASX:CSL; USOTC:CSLLY) is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses, CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 30,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit CSLBehring.com/Vita and follow us on Twitter.com/CSL.
For more information visit csl.com.